CRISPR/Cas9 Reduces Viral Load in a BALB/c Mouse Model of Ocular Herpes Infection.

Biomedicines · 2025 · PMC12292542 · PMID 40722808

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

The CRISPR/Cas9 anti-HSV-1 dose and therapeutic regimen, as well as those of acyclovir, may be significant variables for different models.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.